CinRx Pharma Announces First Study for the Treatment of Obesity

CinRx Pharma announced the first study participant has been dosed in CinFina’s Phase 1 multiple ascending dose (MAD) study of CIN-109.

INVESTOR INQUIRIES

CAREER INQUIRIES

GENERAL INQUIRIES